Abstract:Abstract Background Lumipulse G automated immunoassays represent the most widely used method for the quantification of Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF) 1 . Less invasive blood‐based markers confer a promising tool for AD diagnosis at prodromal stages (Mild Cognitive Impairment‐MCI) 2 . Highly sensitive assays for the quantification of amyloid‐beta (Aβ) and phosphorylated Tau‐181 (p‐Tau181) in blood are showing promising results 3 . In this study we evaluated the clinical performance of the available Lumipulse plasma markers for progression to AD. Method A group of 138 patients (22 neurological controls‐NC, 72 MCI and 44 AD) recruited at the Dementia Clinic of Centro Hospitalar Universitário de Coimbra (CHUC) was included. Data regarding baseline CSF levels of Ab42, Ab40, t‐Tau and p‐Tau181 was available, allowing for characterization into ATN categories 4 . Baseline Ab42, Ab40 and p‐Tau181 levels were determined in stored plasma samples using high‐throughput fully automated Lumipulse assays. Progression from MCI to AD dementia was assessed at follow‐up (mean 5.9±3.0 years; 36 converted ‐MCI‐AD/36 stable ‐MCI‐St). Result In the total cohort, correlations between CSF and plasma were moderate for p‐Tau 181 (r = 0.61, p<0.001), weak for Aβ42 (r = 0.28, p = 0.001) and non‐significant for Aβ40 (r = ‐0.05, p = 0.54). Plasma p‐Tau181 levels were significantly increased while Aβ42, Aβ42/Aβ40 and Aβ42/p‐Tau181 were significantly decreased (p<0.001) in patients classified as MCI‐AD and AD in relation both to NC and MCI‐St. Plasma p‐Tau181 showed a robust performance in differentiating NC+MCI‐St vs. MCI‐AD+AD (AUC = 0.89, 95%CI:0.83‐0.94), MCI‐St vs. MCI‐AD (AUC = 0.89, 95%CI:0.81‐0.96) and CSF A+ vs. A‐ (AUC = 0.84, 95%CI:0.77‐0.91). Plasma Aβ42/p‐Tau181 gave similar AUC results (AUCs = 0.88, 0.84 and 0.83) and showed no significant differences compared to p‐Tau181 alone (p = 0.34, 0.33 and 0.92). For MCI‐St vs. MCI‐AD, when maximizing for sensitivity (0.92, specificity 0.67), baseline plasma p‐Tau181 levels higher than 1.69 pg/mL predicted future AD dementia (HR = 11.5; 95%CI = 10.9‐12.1). Conclusion Our results show that the measurement of p‐Tau181 in peripheral blood has great potential as a non‐invasive prognostic screening tool for AD dementia in MCI patients. 1. Delaby C, et al. Alzheimer’s Dement . 2021; 2.Teunissen CE, et al. Lancet Neurol . 2022; 3.Palmqvist S, et al. Nat Med . 2021; 4.Jack CR, et al. Alzheimer’s Dement . 2018

Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer's disease in cerebrospinal fluid

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts

Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease

Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer’s Disease in Amnestic Mild Cognitive Impairment Subjects

Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research

Benchmarking of a multi-biomarker low-volume panel for Alzheimers Disease and related dementia research

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease

Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer disease

EXPRESS: New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment.

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort

Fully Automated Lumipulse Plasma Amyloid and phosphorylated Tau assays for Progression to Alzheimer’s disease in Mild Cognitive Impairment patients

Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer's disease: a real-world study

P3-238: imr-assayed plasma aβ42 and t-tau classified mild cognitive impaired and mild alzheimer's disease subjects with high accuracies in a multi-country cross-sectional study

Automatic assessment of classical Alzheimer’s disease biomarkers in paired cerebrospinal fluid and plasma samples

Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status

Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology